2.83

5.99% +0.16

Alpha Tau Medical Ltd (DRTS)

Overview News Price History Discussions Forecast

Alpha Tau Medical Ltd stock is currently priced at $2.83, with a 24-hour trading volume of 113.33K. It has seen a +5.99% increased in the last 24 hours and a +5.20% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.68 pivot point. If it approaches the $2.85 resistance level, significant changes may occur.

Previous Close:

$2.67

Open:

$2.665

24h Volume:

113.33K

Market Cap:

$197.17M

Revenue:

Net Income/Loss:

$-29.16M

P/E Ratio:

-8.8438

EPS:

-0.32

Net Cash Flow:

$-29.35M

1W Performance:

+9.27%

1M Performance:

+5.20%

6M Performance:

-7.21%

1Y Performance:

-15.52%

1D Range:

$2.665

$3.14

52W Range:

$2.1501

$4.8001

Alpha Tau Medical Ltd Stock (DRTS) Company Profile

Name

Alpha Tau Medical Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 3 577 4115

Address

Building B3, 4th Floor 5 Kiryat Hamada Street, Jerusalem

Employee

Twitter

Next Earnings Date

2023-05-23

Latest SEC Filings

DRTS's Discussions on Twitter

Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Apr-08-22	Initiated	Piper Sandler	Overweight
Apr-04-22	Initiated	Citigroup	Buy

Alpha Tau Medical Ltd Stock (DRTS) Latest News

Alpha Tau Medical's (DRTS) Buy Rating Reiterated at HC Wainwright - Defense World

Defense World

Alpha Tau Medical's (DRTS) Buy Rating Reiterated at HC Wainwright - MarketBeat

MarketBeat

Inspire Medical Systems (NYSE:INSP) versus Alpha Tau Medical (NASDAQ:DRTS) Financial Survey - Defense World

Defense World

Inspire Medical Systems (NYSE:INSP) versus Alpha Tau Medical (NASDAQ:DRTS) Financial Survey - Defense World

Defense World

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer - Marketscreener.com

Marketscreener.com

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer - Yahoo Finance

Yahoo Finance

Alpha Tau Medical Ltd Stock (DRTS) Financials Data

Alpha Tau Medical Ltd (DRTS) Net Income 2024

DRTS net income (TTM) was -$29.16 million for the quarter ending December 31, 2023, a +13.64% increase year-over-year.

Alpha Tau Medical Ltd (DRTS) Cash Flow 2024

DRTS recorded a free cash flow (TTM) of -$29.35 million for the quarter ending June 30, 2023.

Alpha Tau Medical Ltd (DRTS) Earnings per Share 2024

DRTS earnings per share (TTM) was -$0.42 for the quarter ending December 31, 2023, a +35.38% growth year-over-year.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers. The company was founded in 2015 and is headquartered in Jerusalem, Israel.